Glofitamab  (Synonyms: 格菲妥单抗; RO7082859)

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL)^[1][2][3][4].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Glofitamab (0.1 µg/mL, 48 小时) 与 FAP-IL2v (HY-P99902) 或 FAP-4-1BBL 联合使用刺激淋巴瘤肿瘤微环境 (TMEs) 中 CD8+ 肿瘤浸润淋巴细胞 (TILs) 上 4- 1bb (CD137) 的表达和增强型弥漫性大 B 细胞淋巴瘤 (DLBCL) 细胞死亡^[4]。
Glofitamab (0.2-200 ng/mL, 16 小时) 介导的 DLBCL 细胞杀伤作用需要形成稳定的 T 效应细胞-肿瘤细胞突触^[5]。
Glofitamab 对经 Obinutuzumab (Gpt) (HY-P9910) 预处理瞬时降低的 T 淋巴细胞亚群，NK 细胞和单核细胞无影响^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Glofitamab (0.3-100 μg/kg，单剂量静脉注射) 可诱导食蟹猴体内细胞因子 (IL-1Ra, IL-2, IL-5, IL-6, IL-8, IL-10, G-CSF, IFN-γ 和 TNF-α) 水平呈剂量依赖性升高^[3]。
Glofitamab (0.5 mg/kg, 静脉注射, 单剂量) 在小鼠中诱导早期和持久的 T 细胞结合和活性^[5]。

Glofitamab (静脉注射, 单次剂量) 在有或没有 Obinutuzumab (Gpt: 50 mg/kg) 处理的猕猴中的药代动力学参数 (MeSt: 机制研究；MTD: 最大耐受剂量)^[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2229047-91-8

液体

Colorless to light yellow

格菲妥单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa/lambda with domain crossover, trivalent

• 
  Flow cytometry analysis of Jurkat cells labelling CD3 with Glofitamab at 200 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
• 
  Flow cytometry analysis of Raji cells labelling CD20 with Glofitamab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).

• [1]. Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970.  [Content Brief]

  [2]. Bröske AE, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6(3):1025-1037.  [Content Brief]

  [3]. Frances N, et al. Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. J Pharm Sci. 2022 Apr;111(4):1208-1218.  [Content Brief]

  [4]. Apollonio B, et al. Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma. J Clin Invest. 2023 Jul 3;133(13):e166070.  [Content Brief]

  [5]. Cremasco F, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021 Jan 6;16(1):e0241091.  [Content Brief]